NasdaqGM:STAA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has STAAR Surgical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STAA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

21.0%

STAA

-1.1%

US Medical Equipment

-1.4%

US Market


1 Year Return

153.4%

STAA

23.8%

US Medical Equipment

17.8%

US Market

Return vs Industry: STAA exceeded the US Medical Equipment industry which returned 24.8% over the past year.

Return vs Market: STAA exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

STAAIndustryMarket
7 Day21.0%-1.1%-1.4%
30 Day29.0%5.2%4.7%
90 Day27.6%6.7%8.2%
1 Year153.4%153.4%24.8%23.8%20.5%17.8%
3 Year447.7%447.7%73.9%69.4%42.2%32.7%
5 Year760.9%760.9%145.2%126.2%83.4%62.7%

Price Volatility Vs. Market

How volatile is STAAR Surgical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is STAAR Surgical undervalued compared to its fair value and its price relative to the market?

428.39x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: STAA ($71.2) is trading above our estimate of fair value ($44.55)

Significantly Below Fair Value: STAA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: STAA is poor value based on its PE Ratio (428.4x) compared to the US Medical Equipment industry average (50.8x).

PE vs Market: STAA is poor value based on its PE Ratio (428.4x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: STAA is poor value based on its PEG Ratio (4.4x)


Price to Book Ratio

PB vs Industry: STAA is overvalued based on its PB Ratio (18.7x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is STAAR Surgical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

96.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STAA's forecast earnings growth (96.5% per year) is above the savings rate (2.2%).

Earnings vs Market: STAA's earnings (96.5% per year) are forecast to grow faster than the US market (22.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: STAA's revenue (21.3% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: STAA's revenue (21.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STAA's Return on Equity is forecast to be low in 3 years time (18%).


Next Steps

Past Performance

How has STAAR Surgical performed over the past 5 years?

68.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STAA has high quality earnings.

Growing Profit Margin: STAA's current net profit margins (5%) are lower than last year (5.8%).


Past Earnings Growth Analysis

Earnings Trend: STAA has become profitable over the past 5 years, growing earnings by 68.7% per year.

Accelerating Growth: STAA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: STAA had negative earnings growth (-5.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (2.5%).


Return on Equity

High ROE: STAA's Return on Equity (4.3%) is considered low.


Next Steps

Financial Health

How is STAAR Surgical's financial position?


Financial Position Analysis

Short Term Liabilities: STAA's short term assets ($182.5M) exceed its short term liabilities ($31.6M).

Long Term Liabilities: STAA's short term assets ($182.5M) exceed its long term liabilities ($11.8M).


Debt to Equity History and Analysis

Debt Level: STAA's debt to equity ratio (0.8%) is considered satisfactory.

Reducing Debt: STAA's debt to equity ratio has reduced from 10.2% to 0.8% over the past 5 years.

Debt Coverage: STAA's debt is well covered by operating cash flow (1011.2%).

Interest Coverage: STAA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is STAAR Surgical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STAA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STAA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STAA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STAA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STAA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Caren Mason (66 yo)

5.58yrs

Tenure

US$3,616,037

Compensation

Ms. Caren L. Mason has been the Chief Executive Officer and President of STAAR Surgical Company since March 1, 2015. Ms. Mason served as the Chief Executive Officer of Verinata Health, Inc. from April 2011 ...


CEO Compensation Analysis

Compensation vs Market: Caren's total compensation ($USD3.62M) is below average for companies of similar size in the US market ($USD5.63M).

Compensation vs Earnings: Caren's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Caren Mason
CEO, President & Director5.58yrsUS$3.62m0.096%
$ 3.1m
Keith Holliday
Chief Technology Officer3.58yrsUS$1.07m0.025%
$ 815.7k
Hans-Martin Blickensdoerfer
Senior VP of Commercial Operations and Director of Markets - Europe & China3.92yrsUS$1.03m0.28%
$ 9.1m
Scott Barnes
Chief Medical Officer3yrsUS$1.25m0.024%
$ 785.3k
Patrick Williams
Chief Financial Officer0.25yrno datano data
Graydon Hansen
Senior Vice President of Global Operations2.92yrsno data0.029%
$ 941.2k
Brian Moore
Vice President of Investorno datano datano data
Samuel Gesten
Chief Legal Officer & Corporate Secretary3.5yrsUS$989.43k0%
$ 0
William Goodmen
Vice President of Global Human Resources10.17yrsno datano data
James Francese
Senior Vice President of Commercial Operations - North America & APAC3.92yrsUS$577.79k0.097%
$ 3.1m
Denise McEachern
Global Head of Regulatory Affairs & Quality Assurance5.83yrsno datano data
Philippe Subrin
VP of Collamer Lens Manufacturing & GM of Nidau Operations2.92yrsUS$558.70kno data

3.6yrs

Average Tenure

58yo

Average Age

Experienced Management: STAA's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Caren Mason
CEO, President & Director5.58yrsUS$3.62m0.096%
$ 3.1m
Gilbert Kliman
Independent Director0.33yrno data0%
$ 0
Stephen Farrell
Independent Director4.75yrsUS$203.40k0.013%
$ 413.5k
Louis Silverman
Independent Chairman4.33yrsUS$230.51k0.060%
$ 2.0m
Thomas Frinzi
Independent Director0.33yrno data0.0046%
$ 150.7k
John Moore
Independent Director12.75yrsUS$190.27k0.051%
$ 1.7m
Brian Williams
Member of Optometric Advisory Council11.92yrsno datano data

4.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: STAA's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: STAA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Company Information

STAAR Surgical Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: STAAR Surgical Company
  • Ticker: STAA
  • Exchange: NasdaqGM
  • Founded: 1982
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$3.261b
  • Shares outstanding: 45.81m
  • Website: https://www.staar.com

Number of Employees


Location

  • STAAR Surgical Company
  • 25651 Atlantic Ocean Drive
  • Lake Forest
  • California
  • 92630
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STAANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 1983
SR3DB (Deutsche Boerse AG)YesCommon StockDEEURJul 1983

Biography

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The comp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 23:51
End of Day Share Price2020/10/21 00:00
Earnings2020/07/03
Annual Earnings2020/01/03


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.